MT-ND5
ENSG00000198786
Target class
Enzyme
Chromosome
Mitochondrial
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MT-ND5
- Gene name
- Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5
- Gene symbol
- MT-ND5
- Previous gene symbols
- MTND5
- Protein name
- NADH-ubiquinone oxidoreductase chain 5 (EC 7.1.1.2) (NADH dehydrogenase subunit 5)
- ND5
- NAD5
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|Mitochondrially encoded protein coding genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 11,792.8
- Tissue specificity (Gini)
- 0.26
- Tissue specificity (tau)
- 0.496
- KEGG gene identifiers
- hsa:4540
- Protein interaction confidence
- 0.929168
- Protein interaction partners
- 101
- R-HSA-5419276
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 14148
- Start position
- 12337
- Chromosome
- Mitochondrial
- Strand
- Forward
- Mitochondrion inner membrane
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.495609
- Expression inequality (Gini)
- 0.259727
Expression in transcripts per million
- Brain - Putamen (basal ganglia)
- 11,792.8
- Brain - Caudate (basal ganglia)
- 11,326.2
- Heart - Left Ventricle
- 11,186.8
- Heart - Atrial Appendage
- 10,922
- Brain - Nucleus accumbens (basal ganglia)
- 10,200.7
Expression in transcripts per million
- Brain - Putamen (basal ganglia)11,792.8
- Brain - Caudate (basal ganglia)11,326.2
- Heart - Left Ventricle11,186.8
- Heart - Atrial Appendage10,922
- Brain - Nucleus accumbens (basal ganglia)10,200.7
- Brain - Hypothalamus9,718.36
- Muscle - Skeletal9,539.67
- Brain - Hippocampus9,476.74
- Brain - Substantia nigra9,247.18
- Brain - Amygdala9,126.8
- Brain - Cortex9,001.82
- Fallopian Tube8,581.9
- Brain - Spinal cord (cervical c-1)8,432.89
- Brain - Anterior cingulate cortex (BA24)8,413.75
- Stomach8,208.02
- Esophagus - Gastroesophageal Junction8,142.7
- Small Intestine - Terminal Ileum7,910.63
- Esophagus - Muscularis7,624.05
- Skin - Not Sun Exposed (Suprapubic)7,146.04
- Brain - Frontal Cortex (BA9)7,119.66
- Kidney - Cortex7,005.89
- Adrenal Gland6,584.28
- Skin - Sun Exposed (Lower leg)6,442.18
- Bladder6,395.82
- Brain - Cerebellum6,371.77
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0032981
- GO:0005739
- GO:0005743
- GO:0045271
Molecular functions
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor